These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 7815502)

  • 1. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.
    Kulkarni AB; Collins PL; Bacik I; Yewdell JW; Bennink JR; Crowe JE; Murphy BR
    J Virol; 1995 Feb; 69(2):1261-4. PubMed ID: 7815502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.
    Kulkarni AB; Morse HC; Bennink JR; Yewdell JW; Murphy BR
    J Virol; 1993 Jul; 67(7):4086-92. PubMed ID: 7685408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.
    Kulkarni AB; Connors M; Firestone CY; Morse HC; Murphy BR
    J Virol; 1993 Feb; 67(2):1044-9. PubMed ID: 8419638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
    Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
    J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
    Wyatt LS; Whitehead SS; Venanzi KA; Murphy BR; Moss B
    Vaccine; 1999 Oct; 18(5-6):392-7. PubMed ID: 10519927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon.
    Bembridge GP; Lopez JA; Cook R; Melero JA; Taylor G
    J Virol; 1998 May; 72(5):4080-7. PubMed ID: 9557697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo.
    Aung S; Tang YW; Graham BS
    J Virol; 1999 Nov; 73(11):8944-9. PubMed ID: 10515999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.
    Connors M; Collins PL; Firestone CY; Murphy BR
    J Virol; 1991 Mar; 65(3):1634-7. PubMed ID: 1995956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions.
    Taylor G; Thomas LH; Furze JM; Cook RS; Wyld SG; Lerch R; Hardy R; Wertz GW
    J Gen Virol; 1997 Dec; 78 ( Pt 12)():3195-206. PubMed ID: 9400970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.
    Openshaw PJ; Anderson K; Wertz GW; Askonas BA
    J Virol; 1990 Apr; 64(4):1683-9. PubMed ID: 2319650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.
    Openshaw PJ; Clarke SL; Record FM
    Int Immunol; 1992 Apr; 4(4):493-500. PubMed ID: 1591217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.
    Bembridge GP; Lopez JA; Bustos R; Melero JA; Cook R; Mason H; Taylor G
    J Virol; 1999 Dec; 73(12):10086-94. PubMed ID: 10559323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that the amino acid region 124-203 of glycoprotein G from the respiratory syncytial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection.
    Simard C; Nadon F; Séguin C; Trudel M
    Antiviral Res; 1995 Dec; 28(4):303-15. PubMed ID: 8669890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus.
    Bastien N; Trudel M; Simard C
    Virology; 1997 Jul; 234(1):118-22. PubMed ID: 9234952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.
    Srikiatkhachorn A; Braciale TJ
    J Exp Med; 1997 Aug; 186(3):421-32. PubMed ID: 9236194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein.
    Trudel M; Nadon F; Séguin C; Binz H
    Virology; 1991 Dec; 185(2):749-57. PubMed ID: 1720589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.